| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Endocrine System | ||
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Endocrine System | ||
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Endocrine System |
Recent Updates
Recently added Catalysts
Sana Biotechnology, Inc.$3.28
+0.16 (+5.03%)
D 25Pipeline Score Richly Valued Biotech · Clinical
Market Cap
854.36 M
EPS
-0.94
P/E Ratio
-
Value Trade
8.11 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
28.72 M
Operating CF
-37.38 M
Total Assets
373.59 M
Total Liabilities
254.35 M
Equity
119.24 M
D/E Ratio
12,345
0.66 %
Week
-17.91 %
1 Month
-24.94 %
3 Month
-4.36 %
6 Month
-84.67 %
5 Year
-91.23 %
All Time
Cash Data
Cash Position
101.14 M
Monthly Burn
12.46 M
Runway
5.5 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
3.58 M
52 Week Range
1.98 - 6.55
% held by Insiders
37.57 %
% held by Institutions
54.09 %
Enterprise Value
824.35 M
Total Shares
270.00 M
Short %
22.87 %
Float Shares
157.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sana Biotechnology, Inc.
352Total events
6Upcoming
44Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T2IND Submission
Subscribe to view catalyst details
Event history 2
TBD
▲Full ResultsUP421Clinical Data
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | SC262 | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | SC262 | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | SC262 | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D25
Pipeline Score $41M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 25%
Micro Cap (rank 686 of 913)
Percentile RankSana Biotechnology, Inc. faces pipeline headwinds (25/100), with $283M risk-adjusted pipeline value, led by SC262 in Non Hodgkin's Lymphoma (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SC262 Small molecule | Non Hodgkin's Lymphoma | Phase 1 | NCT06285422 | 5% | $152M | ACTIVE NOT_RECRUITING | 6 | STALLED | D (20) | Mar 1, 2029 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SC451 | Type 1 Diabetes | Phase 1/2 | 2026-07-13 | C-peptide levels at month 14 are comparable to those observed Read More | Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes Read More | |
SC451 | Type 1 Diabetes | Phase 1/2 | 2026-07-13 | C-peptide levels at month 14 are comparable to those observed Read More | Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes Read More | |
SC451 | Type 1 Diabetes | Phase 1/2 | 2026-07-13 | C-peptide levels at month 14 are comparable to those observed Read More | Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SANA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SANA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SANA▼ -5.5%on this news· ran to -18% by day 3
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology announced a follow-up publication in NEJM detailing long-term data on hypoimmune-modified islet cell transplantation for type 1 diabetes. The study indicates that these modified cells can function long-term without immunosuppression, achieving significant insulin production. Sana plans to file an IND application and initiate a Phase 1/2 trial for SC451, aiming for a one-time treatment solution.
Read more →SANASana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Sana Biotechnology announced a symposium presentation at the EASD Annual Meeting 2026, showcasing clinical data from a first-in-human study of UP421, an allogeneic islet cell therapy for type 1 diabetes. This therapy utilizes Sana's hypoimmune platform technology and aims to eliminate the need for immunosuppression in patients. The meeting will take place in Milan, Italy from September 28 to October 2, 2026.
Read more →SANASana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology, Inc. announced its participation in two investor conferences in June 2026, where it will present a business overview and updates. The presentations will take place at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of the presentations will be available on the company's website.
Read more →SANASana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
Sana Biotechnology, Inc. has successfully sold approximately 21.6 million shares of its common stock through its at-the-market facility for net proceeds totaling around $69 million. This capital raise, which includes contributions from RA Capital Management and an earlier $25 million investment from the Mayo Clinic, increases the total funds raised by the company to roughly $94 million since the end of Q1 2026. The additional capital is expected to extend Sana's operational cash runway to mid-2027, supporting its focus on developing engineered cell therapies.
Read more →SANASana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Sana Biotechnology presented promising preclinical data for its SG293 CAR T cell therapy at the ASGCT 2026 Annual Meeting. The therapy demonstrated effective cell-specific delivery and significant B cell depletion in non-human primates without the need for lymphodepleting chemotherapy. This innovative approach aims to provide targeted treatment options for blood cancers and autoimmune disorders, with clinical trials expected to commence soon.
Read more →SANASana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451
Sana Biotechnology reported its first quarter 2026 financial results, highlighting a strategic collaboration with Mayo Clinic aimed at enhancing treatment for type 1 diabetes. The company is progressing towards initiating Phase 1 trials for its gene-modified product SC451 and its CAR T-cell candidate SG293 within the year. Positive clinical results were shared concerning the UP421 therapy, showcasing its effectiveness without immunosuppression. Sana's financial profile shows a cash position of $101.1 million, allowing for continued operational support into 2027.
Read more →SANASana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Sana Biotechnology, Inc. will present at the BofA Securities 2026 Healthcare Conference on May 12, 2026. CEO Steve Harr will provide a business overview during the webcast, which will be accessible on the company's Investor Relations page. A replay will be available for 30 days post-conference.
Read more →SANASana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
Sana Biotechnology announced that its abstract on SG293, a CD19-directed in vivo CAR T product, has been accepted for oral presentation at the ASGCT 2026 Annual Meeting. This innovative therapy utilizes proprietary fusogen technology to target CD8+ T cells, aiming to improve treatment for B-cell cancers and autoimmune diseases. The conference will take place from May 11-15, 2026, in Boston, MA.
Read more →SANA▲ +8.4%on this news
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451
Sana Biotechnology and Mayo Clinic have announced a strategic collaboration to advance SC451, an investigational therapy for type 1 diabetes. This partnership aims to enhance the development and accessibility of potentially curative treatments. Mayo Clinic will invest in Sana and leverage its expertise to improve clinical protocols and patient care for SC451, which is designed to provide long-term glucose control without ongoing insulin therapy.
Read more →SANA▲ +8.7%on this news
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology reported positive 14-month results from a first-in-human study of islet cell transplantation for Type 1 diabetes, utilizing hypoimmune-modified cells without immunosuppression. The study showed sustained insulin production and improved glycemic control, with no safety issues reported. The company plans to file an IND application for its SC451 therapy and initiate a Phase 1 trial soon.
Read more →SANASana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Sana Biotechnology reported positive clinical results for its UP421 type 1 diabetes study, demonstrating safety and efficacy without immunosuppression. The company is advancing its SC451 therapy and expects to file an IND application soon. Additionally, they anticipate generating first-in-human data for their SG293 CAR T candidate. Financially, Sana raised $133.7 million, ensuring a cash runway into late 2026.
Read more →SANASana Biotechnology to Present at March 2026 Investor Conferences
Sana Biotechnology, Inc. has announced its participation in two investor conferences in March 2026. The company will webcast its presentations, which will include a business overview and updates on its engineered cell therapies. Replays of the presentations will be available for 30 days on their website.
Read more →SANASana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer
Sana Biotechnology has appointed Brian Piper as Executive Vice President and Chief Financial Officer. Piper brings extensive experience from various roles in the biopharmaceutical industry, including his previous positions at Scorpion Therapeutics and Prelude Therapeutics. His leadership is expected to be pivotal as the company advances its clinical programs for type 1 diabetes and B-cell related diseases.
Read more →SANAThis presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securit
Sana Biotechnology, Inc. presented forward-looking statements about its strategic goals and advancements in developing therapies for Type 1 diabetes (T1D). The company is positioning itself to file an Investigational New Drug application for SC451 and commence Phase 1 trials in 2026, showcasing progress in immune evasion techniques. Despite the advancements, challenges remain, including the uncertainties surrounding drug development and the requirement for chronic immunosuppression in existing therapies.
Read more →SANA▲ +8.5%on this news
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sana Biotechnology, Inc. announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will feature insights from CEO Steve Harr and provide a business overview. The webcast will be available on the company’s Investor Relations page, along with a 30-day replay option. This event highlights Sana's focus on engineered cell therapies.
Read more →SANA▼ -9.7%on this news
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Sana Biotechnology announced a publication in Nature Biotechnology detailing the successful in vivo gene editing of human hematopoietic stem cells (HSCs) using its Fusogen technology in preclinical models. This advancement showcases the technology's potential to treat diseases such as sickle cell disease and beta thalassemia without the need for conditioning chemotherapy. The publication underscores the ability of Fusogen to deliver various gene-editing tools effectively and safely.
Read more →SANASana Biotechnology to Present at December 2025 Investor Conferences
Sana Biotechnology, Inc. will present at two investor conferences in December 2025, featuring a business overview from CEO Steve Harr. The presentations will be accessible via webcast on the company's Investor Relations page, with replays available for 30 days. This engagement highlights Sana's commitment to transparency and investor relations.
Read more →SANASana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates
Sana Biotechnology reported its Q3 2025 financial results, highlighting a strategic shift towards type 1 diabetes and in vivo CAR T programs. The company aims to file an IND for SC451 by 2026 and SG293 by 2027, following positive clinical results. Despite a strong cash position, Sana has suspended its allogeneic CAR T studies to focus resources on these promising therapies.
Read more →SANASana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit
Sana Biotechnology, Inc. will present at the TD Cowen Immunology & Inflammation Summit on November 12, 2025. CEO Steve Harr will provide a business overview during the webcast. The presentation will be available for replay on the company's website for 30 days post-conference, emphasizing Sana's commitment to transparency and engagement with stakeholders.
Read more →SANASana Biotechnology to Present at September 2025 Investor Conferences
Sana Biotechnology, Inc. announced it will webcast presentations at four investor conferences in September 2025. These presentations will include a business overview and updates on the company's operations. The webcasts will be available on their Investor Relations page, with replays accessible for 30 days post-conference.
Read more →SANASana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sana Biotechnology announced the successful closing of its public offering, selling 3,358,208 shares at $3.35 each. This exercise of the underwriters' option resulted in total gross proceeds of approximately $86.3 million. The offering was managed by major financial institutions, reflecting strong market confidence in Sana's engineered cell therapies.
Read more →SANASana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells t
Sana Biotechnology reported encouraging financial results and business updates for Q2 2025, highlighted by positive clinical outcomes from their type 1 diabetes study utilizing hypoimmune-modified pancreatic islet cells. The company has also received favorable feedback from the FDA regarding their master cell bank for SC451, which is expected to support future drug applications. Financings raised approximately $105 million will provide a financial runway until at least the second half of 2026, facilitating ongoing clinical trials and new IND filings. Further data from multiple ongoing trials is anticipated through 2025.
Read more →SANA▼ -30.1%on this newsshared move
Sana Biotechnology Announces Pricing of Public Offering
Sana Biotechnology has announced the pricing of its public offering, which includes 20,895,522 shares of common stock priced at $3.35 each. The offering aims to raise approximately $75 million, with a closing date anticipated around August 8, 2025. The company has granted underwriters a 30-day option to purchase additional shares.
Read more →SANA▼ -30.1%on this newsshared move
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Sana Biotechnology has announced a proposed public offering of $75 million in common stock and pre-funded warrants. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares. Major financial institutions are managing the offering, which aims to support the company's mission of delivering engineered cell therapies.
Read more →SANA▲ +6.4%on this news· ran to -25% by day 3shared move
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Sana Biotechnology announced the publication of groundbreaking clinical data in the New England Journal of Medicine, demonstrating that their hypoimmune-modified pancreatic islet cells can be transplanted without immunosuppression. The study showed that these cells not only persist but also function effectively in a patient with type 1 diabetes, producing insulin independently. This advancement could pave the way for a functional cure for the disease.
Read more →SANA▼ -8.7%on this news
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology announced positive six-month results from a first-in-human study of its hypoimmune (HIP) technology for treating type 1 diabetes. The study demonstrated that transplanted pancreatic islet cells survived, produced insulin, and evaded immune detection without requiring immunosuppression. These findings suggest a potential functional cure for diabetes, with ongoing evaluations planned.
Read more →SANASana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Sana Biotechnology will present data from a first-in-human study of UP421, an engineered islet cell therapy for type 1 diabetes, at the 85th Annual ADA Scientific Sessions. The therapy utilizes hypoimmune technology and does not require immunosuppression. The presentation will take place in Chicago from June 20-23, 2025.
Read more →SANA▲ +12.5%on this news
Sana Biotechnology to Present at June 2025 Investor Conferences
Sana Biotechnology, Inc. has announced its participation in two investor conferences in June 2025, where it will provide updates on its business and development focus on engineered cells. The presentations will be webcasted for investors, with replays available for 30 days after the events. This initiative aims to improve transparency and engagement with stakeholders as the company continues its mission to innovate in therapeutic solutions. However, the company also acknowledges the uncertainties and risks associated with future drug development and operational prospects.
Read more →SANA▲ +24.4%on this news
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Sana Biotechnology, Inc., alleging that the company made misleading statements regarding its financial stability and product viability during the class period from March 17, 2023, to November 4, 2024. Plaintiffs claim that the company's executives overstated its operational capacity and concealed significant risks concerning ongoing projects. Affected investors are encouraged to participate in the lawsuit, which aims to recover losses incurred during this timeframe. The law firm handling the case operates on a contingency fee basis, meaning they will only be compensated through successful recoveries.
Read more →SANASANA DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action – SANA
Rosen Law Firm reminds investors of Sana Biotechnology, Inc. of an important May 20, 2025 deadline to join a class action lawsuit concerning alleged misleading statements made by the company. The lawsuit suggests that Sana has insufficient funds to continue operations, and its product candidates may not be as promising as stated. Investors who purchased securities during the defined class period may be entitled to compensation without upfront fees. A lead plaintiff must act before the deadline to represent other class members in the litigation.
Read more →SANASANA Investors Have the Opportunity to Lead the Sana Biotechnology Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP is investigating Sana Biotechnology for potential securities fraud, encouraging affected investors to seek legal counsel. The firm has identified significant risks affecting the company's financial stability and product pipeline. Major announcements regarding headcount reductions and development halts have led to a notable drop in stock prices. Additionally, allegations have surfaced suggesting misleading statements were made by the company, prompting legal action.
Read more →SANASana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA
Sana Biotechnology, Inc. is facing a class action lawsuit alleging securities fraud from March 17, 2023, to November 4, 2024. The complaint outlines that the company may not have the necessary funds to sustain its operations or advance its product candidates. It accuses the defendants of making misleading public statements regarding the viability of certain treatments and financial health of the company. Investors have until May 20, 2025, to seek appointment as lead plaintiff in this case, which could lead to compensation without out-of-pocket costs.
Read more →SANA▲ +9.9%on this newsshared move
Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference
Sana Biotechnology, Inc. will present at the BofA Securities 2025 Healthcare Conference on May 13, 2025. The presentation, led by CEO Steve Harr, aims to provide an overview and update on the company's business strategy and focus on engineered cell therapies. The webcast will be accessible on the company's Investor Relations page, and a replay will be available for 30 days. The company is dedicated to advancing medical treatments and changing patient care standards through technology and innovation.
Read more →SANA▲ +9.9%on this newsshared move
Sana Biotechnology, Inc. Class Action: The Gross Law Firm Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA
Sana Biotechnology, Inc. is facing a class action lawsuit with allegations that it made materially false and misleading statements regarding its financial condition and product candidates. The claims suggest that the company is at significant risk of inadequate funds to support its operations and that its oncology candidates are less promising than previously stated. Shareholders are urged to register for the lawsuit before the lead plaintiff deadline of May 20, 2025. The Gross Law Firm is handling the case and encourages impacted investors to participate.
Read more →SANA▲ +6.5%on this newsshared move
Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet c
Sana Biotechnology reported its financial results for the first quarter of 2025, highlighting advances in its type 1 diabetes study with positive clinical results from hypoimmune-modified pancreatic islet cells. The company is enrolling patients in two clinical trials for autoimmune diseases and B-cell malignancies and is set to file multiple investigational new drug applications by 2026. Despite a strong cash position of $104.7 million, Sana continues to face financial losses and high research expenses during this phase of development.
Read more →SANA▲ +6.5%on this newsshared move
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Sana Biotechnology, Inc. is facing a class action lawsuit filed by Levi & Korsinsky on behalf of investors affected by alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims that the company misrepresented its financial stability and the potential of its product candidates, which could lead to significant operational challenges. Shareholders are encouraged to respond by May 20, 2025, to potentially participate in the lawsuit.
Read more →SANASana Biotechnology, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SANA
Sana Biotechnology, Inc. is being sued for alleged violations of securities laws, with investors encouraged to contact The Gross Law Firm for potential participation in class action. The lawsuit claims that the company misled shareholders regarding its financial position and the viability of certain drug candidates. Specifically, it alleges that Sana faces significant risks related to funding for operations and product development. The deadline for shareholders to register for the class action is May 20, 2025.
Read more →SANASana Biotechnology, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA
Sana Biotechnology, Inc. is embroiled in a class action securities lawsuit filed by Levi & Korsinsky, LLP, which seeks to assist investors who suffered losses from alleged securities fraud between March 17, 2023, and November 4, 2024. The complaint asserts that company officials made misleading statements regarding the company's financial health and the status of its product candidates. Key allegations include insufficient funding to support ongoing operations, potential cuts to product development, and overstated financial capabilities. Investors may contact Levi & Korsinsky to learn about their rights and potential compensation.
Read more →SANA▼ -7.1%on this newsshared move
Sana Biotechnology, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. May 20, 2025 Deadline to file Lead Plaintiff Motion.
The Portnoy Law Firm has announced a class action on behalf of investors in Sana Biotechnology, Inc. who purchased securities between March 17, 2023, and November 4, 2024. Investors have until May 20, 2025, to file a lead plaintiff motion. The lawsuit alleges that Sana's management made materially false statements about the company's financial health and product development, which misled investors about the company's prospects. Specific issues cited include a lack of sufficient capital and the potential discontinuation of some product candidates.
Read more →SANASANA Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information on How to Lead the Class Action Against Sana Biotechnology, Inc.
Robbins LLP has announced a class action lawsuit against Sana Biotechnology, Inc. on behalf of investors who acquired its securities between March 17, 2023, and November 4, 2024. The lawsuit alleges that Sana misled shareholders about its financial health and the viability of its product candidates. Specifically, the complaint claims that the company faced significant operational risks and was likely to cut funding and reduce staff to preserve resources. This resulted in a drop in stock prices when the truth emerged.
Read more →SANA▼ -15.8%on this newsshared move
Sana Biotechnology, Inc. Stockholder News: Robbins LLP Reminds Investors of the Class Action Lawsuit Against SANA
Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023, and November 4, 2024. The lawsuit alleges that Sana misled investors about its financial stability and the viability of product candidates, particularly in oncology and other therapeutic areas. Due to these disclosures, the company's stock price has significantly declined, impacting investors' holdings. Shareholders interested in participating in the class action must file their lead plaintiff papers by May 20, 2025.
Read more →SANA▼ -5.5%on this news· ran to -23% by day 3
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1
Sana Biotechnology has reported encouraging preliminary results from its ongoing type 1 diabetes study, highlighting stable C-peptide production achieved without immunosuppression. The company is also making strides in other clinical trials, namely SC291 and SC262, for various autoimmune diseases and B-cell malignancies, with results expected in 2025. Furthermore, Sana is on track to submit investigational new drug applications for SC451 and SG299 by 2026, bolstered by a strong cash position that supports its research initiatives through 2026.
Read more →SANASana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
Sana Biotechnology, Inc. has announced its participation in the Cowen 45th Annual Health Care Conference, where CEO Steve Harr will deliver a presentation on the company's business updates. The presentation is scheduled for 3:10 p.m. ET on March 3, 2025. Interested parties can access the live webcast on Sana's Investor Relations page, and a replay will be available for 30 days post-event. The company focuses on creating engineered cell therapies aimed at improving patient outcomes.
Read more →SANA▼ -5.5%on this news
Corporate Presentation January 2025 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within t
Sana Biotechnology presented forward-looking statements emphasizing its innovative hypoimmune platform, which is designed to overcome allogeneic rejection. Recent clinical data highlight successful transplantation of HIP-modified pancreatic islets in type 1 diabetes patients, demonstrating both safety and efficacy. This technology is posited to have potential applications across various diseases, including autoimmune disorders and blood cancers. However, the projections carried significant uncertainties and are subject to the outcomes of ongoing research and clinical trials.
Read more →SANA▲ +160.6%on this newsshared move
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sana Biotechnology, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will be led by Steve Harr, the company's President and CEO, and will provide an overview of the company's business strategy and updates. The webcast will be accessible to the public and will remain available for 30 days post-conference.
Read more →SANA▼ -5.7%on this news· ran to +146% by day 1shared move
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology announced promising initial results from a first-in-human study of its HIP-engineered islet cell therapy for type 1 diabetes, which demonstrated that the transplanted cells can evade immune rejection without the need for immunosuppression. C-peptide levels, a marker of insulin production, remained consistent, indicating the functionality and survival of the islet cells post-transplantation. The study showed no safety concerns, providing hope for a scalable and curative treatment for type 1 diabetes. Further evaluation will continue to assess the safety and efficacy of this innovative approach.
Read more →SANASana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Sana Biotechnology announced that the FDA granted Fast Track designation for SC291, aimed at treating relapsed/refractory systemic lupus erythematosus (SLE). The therapy, a hypoimmune CD19-directed allogeneic CAR T cell treatment, is currently being evaluated in the GLEAM trial. The company expects to report initial clinical data by 2025. This designation emphasizes the urgent need for new treatment options in a challenging and underserved patient population.
Read more →SANASana Biotechnology to Present at December 2024 Investor Conferences
Sana Biotechnology, Inc. will present at two investor conferences in December 2024, providing an overview and updates on its business. The company will participate in the Citi 2024 Global Healthcare Conference on December 3 and the Evercore ISI HealthCONx Conference on December 4. These presentations will be available via webcast on Sana's website, with replays accessible for 30 days post-event. The company aims to advance engineered cell therapies for patient treatment.
Read more →SANASana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseas
Sana Biotechnology reported its financial results for Q3 2024, revealing continued advancements in its hypoimmune technology across several clinical trials aimed at type 1 diabetes and B-cell mediated autoimmune diseases. The company maintains a robust cash position of $199 million, which is expected to sustain operations into 2026. Despite optimistic developments, including new leadership and strategic focus, the company reported a net loss of $59.9 million for the quarter, indicating ongoing financial pressures. The operational cash burn is projected to rise, reflecting the evolving landscape of the company's clinical efforts.
Read more →SANASana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
Sana Biotechnology has announced a strategic shift to focus on type 1 diabetes and B-cell mediated autoimmune diseases, halting development on certain oncology programs to consolidate resources. The company anticipates multiple clinical data readouts by 2024 and 2025, following a promising early clinical data for its therapies. This new direction aims to enhance the potential impact on patients and extends the cash runway into 2026. However, the decision comes with challenges, including increased operating cash burn and the need to part with talent.
Read more →SANASana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
Sana Biotechnology, Inc. announced that it will webcast its panel during the Goldman Sachs Cell Therapy Day Conference on October 1, 2024. The presentation will be led by CEO Steve Harr, covering a business overview and updates. The webcast will be accessible on Sana's Investor Relations page, with a replay available for 30 days. The company focuses on engineered cell therapies, aiming to provide innovative solutions for patients.
Read more →SANASana Biotechnology to Present at September 2024 Investor Conferences
Sana Biotechnology, Inc. will webcast presentations at three upcoming investor conferences in September 2024. These conferences include the Morgan Stanley 22nd Annual Global Healthcare Conference, the 2024 Wells Fargo Healthcare Conference, and the HC Wainwright 26th Annual Global Investment Conference. Each presentation will deliver a business overview and update, with replays available for 30 days following the events. Sana focuses on engineered cells as medicines to transform patient care and operates multiple facilities across the United States.
Read more →SANASana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
Sana Biotechnology has appointed Dhaval Patel, M.D., Ph.D., as its new Executive Vice President and Chief Scientific Officer. Patel's extensive background in drug development includes pivotal contributions to multiple FDA-approved therapies. His expertise is expected to enhance Sana's clinical pipeline focused on autoimmune diseases and type 1 diabetes. The company currently has four ongoing clinical trials, indicating a proactive approach towards innovation and patient care.
Read more →SANASana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, an
Sana Biotechnology reported its financial results and business updates for the second quarter of 2024, highlighting advancements in its hypoimmune technology across multiple clinical trials. The company is currently enrolling patients in several trials targeting B-cell malignancies and autoimmune diseases, expecting to share initial data in 2024. Financially, Sana has a strong cash position of $251.6 million but also reported a considerable net loss. Nonetheless, the company remains optimistic about its research pipeline and strategic investments in manufacturing capabilities.
Read more →SANASana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
Sana Biotechnology recently announced the publication of novel preclinical data in Nature Biotechnology showing that pluripotent stem cell-derived human glial progenitor cells (hGPCs) can effectively replace diseased glial cells in the brains of Huntington's disease model mice. This advancement provides additional proof-of-concept for SC379, Sana's product candidate aimed at treating various central nervous system disorders. The research indicates that healthy hGPCs can outcompete and eliminate unhealthy cells, paving the way for potential clinical applications. Sana's CEO expressed optimism about the findings and the future of SC379 in treating a range of neurological conditions.
Read more →SANA▼ -5.5%on this news· ran to -25% by day 1
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type
Sana Biotechnology has reported its financial results for the first quarter of 2024, detailing ongoing efforts to treat patients through four clinical trials targeting various indications. The company plans to treat 40-60 patients in 2024 while working on B-cell mediated autoimmune diseases and type 1 diabetes. Despite ongoing trials showing potential, Sana recorded a net loss of $107.5 million, highlighting the financial challenges ahead while maintaining a cash position of $311.1 million to support its initiatives.
Read more →SANASana Biotechnology to Present at May and June 2024 Investor Conferences
Sana Biotechnology, Inc. has announced its participation in three upcoming investor conferences in May and June 2024. The company will present at the Citizens JMP Securities Life Sciences Conference, BofA Securities 2024 Healthcare Conference, and Goldman Sachs 45th Annual Global Healthcare Conference. Each presentation will provide a business overview and be accessible via webcast. Sana aims to highlight its mission of creating engineered cell therapies to improve patient outcomes.
Read more →SANA▼ -5.9%on this news
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune dis
Sana Biotechnology has reported its financial results for Q4 and the full year of 2023, setting a goal to treat 40-60 patients across four trials in oncology and autoimmune diseases in 2024. The company has secured IND clearance for two programs and received positive early data from the SC291 trial, indicating safe dosing and promising immune evasion. With a strong cash position of $205.2 million and recent financing, Sana aims to continue advancing its clinical pipeline. Key data readouts are expected throughout 2024, showcasing potential transformative therapies.
Read more →SANA▲ +7.3%on this newsshared move
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
Sana Biotechnology, Inc. announced it will present at the Cowen 44th Annual Health Care Conference scheduled for March 6, 2024. The presentation will be led by CEO Steve Harr and will include a business overview and updates on the company's initiatives. The event will be available via webcast, allowing for broader access to its content. Sana Biotechnology is committed to developing engineered cell therapies and aims to improve treatment options for patients.
Read more →SANASana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
Sana Biotechnology announced the publication of preclinical data in the journal Cell Stem Cell, showcasing the successful transplantation of HIP-modified pancreatic islet cells in diabetic non-human primates. The study reported that these cells enabled sustained glucose control and insulin independence without the need for immunosuppression over a six-month duration. Future human trials are anticipated to assess the clinical viability of these findings. This research could significantly revolutionize treatment approaches for type 1 diabetes, addressing a critical unmet need.
Read more →SANASana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sana Biotechnology, Inc. has successfully closed its upsized public offering of 21,772,728 shares of common stock, raising around $189.75 million. The offering included the full exercise of an option by underwriters to purchase an additional 4,500,000 shares. The shares were priced at $5.50 each, and pre-funded warrants were also offered. Major financial institutions such as Morgan Stanley and J.P. Morgan managed the offering, which was conducted under an SEC Registration Statement.
Read more →SANASana Biotechnology Announces Pricing of Upsized Public Offering SEATTLE, Feb. 08, 202 4 (GLOBE NEWSWIRE) Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered
Sana Biotechnology, Inc. announced the pricing of its upsized public offering, set to sell 17,272,728 shares at $5.50 each, along with pre-funded warrants. The total expected gross proceeds from the offering are approximately $165.0 million, pending closing conditions. The offering will close on or about February 12, 2024, and a 30-day option for underwriters to purchase an additional 4,500,000 shares has been granted. The company aims to leverage these funds for future initiatives in engineered cell therapies.
Read more →SANAOverview We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause t
Sana Biotechnology emphasizes its belief in the transformative potential of engineered cells in medicine. The company is developing innovative therapies to address various diseases by creating hypoimmune-modified cells to mitigate immune rejection issues. Their ongoing clinical trials, particularly the ARDENT trial, have reported promising early results with no significant adverse events and evidence of immune evasion in patients. Future data from multiple trials is expected to be shared in 2024, highlighting their commitment to advancing gene and cell therapy.
Read more →SANASana Biotechnology Announces Proposed Public Offering of Common Stock
Sana Biotechnology, Inc. has announced its intention to conduct an underwritten public offering for $125 million in common stock, with an additional option for underwriters to purchase up to $18.75 million more. This offering is subject to market conditions and there is no guarantee regarding its completion or the specifics of the terms. Major financial firms like Morgan Stanley and J.P. Morgan are managing the offering, which follows a prior effective registration statement with the SEC. The company aims to use the funds potentially for advancements in its engineered cell therapies.
Read more →SANAThis presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws. All statements other than statements of histor
Sana Biotechnology, Inc. presented its forward-looking statements regarding its strategic goals and pipeline developments. The company is advancing its hypoimmune technology with plans for multiple clinical programs targeting conditions like type 1 diabetes, several cancers, and autoimmune diseases. The presentation also addressed the financial future and operational strategies, highlighting significant risks associated with drug development. However, Sana's innovative approach may provide solutions for the challenges inherent in allogeneic therapies.
Read more →SANASana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
Sana Biotechnology has announced that the FDA has cleared its Investigational New Drug application for SC262, an allogeneic CAR T therapy targeting CD22 for patients with relapsed or refractory B-cell malignancies. This therapy is particularly aimed at patients who have previously failed CD19-directed CAR T therapies, addressing a currently unmet medical need. The hypoimmune technology employed in SC262 may offer improved outcomes by reducing the risk of immune rejection. Initial clinical studies are set to commence, with preliminary data expected by the end of the year.
Read more →SANA▲ +11.9%on this newsshared move
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Sana Biotechnology, Inc. has announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference, where CEO Steve Harr will present a business overview. The presentation is set for January 9, 2024, and will be accessible via a live webcast on the company's Investor Relations page. Following the event, a replay will be available for 30 days. The company focuses on engineered cell therapies, aiming to transform patient care through innovative treatments.
Read more →SANASana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
Sana Biotechnology presented promising preclinical data at the American Society of Hematology Annual Meeting, showcasing its HIP-modified allogeneic CAR T cells' ability to evade immune detection while retaining their therapeutic effects. The research supports the advancement of the CD22-targeted CAR T cell therapy SC262 into human clinical trials, which are scheduled to begin in early 2024. Additionally, fully-human GPRC5D-specific CAR T cells demonstrated significant in vitro and in vivo efficacy against multiple myeloma, marking important progress in Sana's CAR T cell pipeline.
Read more →SANASana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
Sana Biotechnology announced initial clinical data regarding SC291, an allogeneic CAR T cell therapy, showing its ability to evade immune detection while maintaining safety and tolerance. The therapy demonstrated a partial response in a patient with chronic lymphocytic leukemia during the ARDENT Phase 1 trial. This therapy leverages a hypoimmune platform designed to overcome immunologic rejection issues. Future data from the trial are anticipated to further clarify SC291's efficacy and profile in combating cancer.
Read more →SANA▼ -6.7%on this news
Sana Biotechnology to Present at November and December 2023 Investor Conferences
Sana Biotechnology, Inc. has announced its participation in two upcoming investor conferences in November and December 2023. The conferences are the Evercore ISI HealthCONx Conference and the JMP Securities Hematology and Oncology Summit. Sana's presentations will provide a business overview and updates on its engineered cell therapies. The webcasts will be accessible through the company's Investor Relations page, allowing stakeholders to view the presentations and replays for a limited time.
Read more →SANASana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
Sana Biotechnology has received FDA clearance for its Investigational New Drug application for SC291, an allogeneic CAR T therapy aimed at treating multiple B-cell mediated autoimmune diseases like lupus nephritis and ANCA-associated vasculitis. This therapy, derived from healthy donors, promises enhanced scalability in manufacturing and simplifies treatment protocols. Sana plans to initiate patient treatment shortly and anticipates sharing initial safety and efficacy data in 2024. The development of SC291 is part of a broader strategy to address unmet medical needs in autoimmune disease treatment.
Read more →SANA▼ -13.9%on this newsshared move
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates Enrolling Phase 1 ARDENT trial investigating SC291 in patients with refractory B-cell malignancies with initial data expected in 2023 a
Sana Biotechnology has reported its third quarter 2023 financial results, highlighting ongoing enrollment in the Phase 1 ARDENT trial for SC291, targeting B-cell malignancies. The company has submitted an IND for multiple autoimmune diseases and anticipates initial data from various clinical settings in 2023 and 2024. Financially, Sana maintains a robust cash position of $268.6 million, which is projected to sustain operations into 2025. However, the net loss for the first nine months of 2023 reached approximately $195.1 million, raising concerns about financial sustainability amidst ongoing high expenses.
Read more →SANASana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
Sana Biotechnology, Inc. announced that it will have five poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting, scheduled for December 9-12, 2023, in San Diego, CA. The presentations will cover a range of topics, including CAR T cell therapies and in vivo genetic engineering of human hematopoietic stem progenitor cells. This participation underscores Sana's commitment to the development of innovative treatments in hematology.
Read more →SANASana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M Increasi
Sana Biotechnology has announced a strategic shift towards its hypoimmune-related pipeline, with aims to deliver clinical proof of concept data from four programs by 2024. The company is focusing on its ex vivo cell therapy platform, which has shown promising preclinical results, and anticipates initial data from trials in oncology, autoimmune diseases, and type 1 diabetes. Despite these advancements, Sana will reduce its workforce by 29% and delay certain programs, including the SG299 IND submission. The projected 2024 operating burn is expected to be below $200 million, which may extend its financial runway into 2025.
Read more →SANASana Biotechnology to Present at September 2023 Investor Conferences
Sana Biotechnology, Inc. will present at several investor conferences in September 2023, showcasing its progress in engineered cell therapies. Key executives, including CEO Steve Harr and CFO Nate Hardy, will deliver updates on the company's strategy during these events. The presentations will be webcasted and available for replay on the company's Investor Relations page. This highlights Sana’s proactive approach in engaging with investors and sharing its vision for innovative treatments.
Read more →SANASana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect dat
Sana Biotechnology has reported its financial results for Q2 2023 and highlighted advancements in its clinical pipeline. The company is actively enrolling patients in the ARDENT Phase 1 trial for SC291, designed to treat B-cell malignancies, with initial data expected later this year. Sana is also on track to submit Investigational New Drug (IND) applications for SC262 and SG299 targeting hematologic cancers. The firm showcased promising preclinical data regarding hypoimmune-modified islet cells that may offer new treatment options for type 1 diabetes.
Read more →SANASana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
Sana Biotechnology presented promising preclinical data from their hypoimmune and fusogen platforms at the ISSCR 2023 Annual Meeting. Key findings included the potential of HIP-modified CAR T cells to provide durable therapies without the need for immunosuppression, and the effectiveness of HIP-modified islet cells in alleviating diabetes in humanized mice. The company also highlighted advancements in delivering genetic payloads to stem cells. Sana plans to release initial clinical data later this year to further validate these findings.
Read more →SANASana Biotechnology to Present at June 2023 Investor Conferences
Sana Biotechnology, Inc. announced its intention to webcast presentations at two upcoming investor conferences in June 2023. The presentations will include updates from the CEO, Steve Harr, and will take place at the Jefferies Healthcare Conference and the Goldman Sachs 44th Annual Global Healthcare Conference. These events reflect Sana's commitment to improving patient outcomes through engineered cell therapies. The webcasts will be accessible on the company's Investor Relations page, with replays available for 30 days after each event.
Read more →SANASana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year SC
Sana Biotechnology reported its first quarter 2023 results, highlighting the progress of its SC291 Phase 1 trial for B-cell malignancies, which has received FDA Fast Track Designation. The company expects initial clinical data later in the year and plans to submit Investigational New Drug applications for two additional product candidates by year-end. Sana's financial position remains robust with $355 million in cash, sufficient to support multiple readouts through 2025. The firm has also strengthened its R&D leadership, aiming to enhance its research capabilities and outcomes.
Read more →SANASana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
Sana Biotechnology announced the publication of preclinical data in Nature Biotechnology showcasing their hypoimmune-engineered cells, which successfully evade immune detection and demonstrate long-term survival without immunosuppression. The studies, conducted in non-human primates, indicated that these modified cells function effectively while remaining immune-evasive. The findings suggest significant potential for hypoimmune technology in allogeneic transplants, including its application to diabetes treatment. Sana plans to incorporate this technology into multiple therapeutic candidates and anticipates clinical data later this year.
Read more →SANA▲ +8.9%on this newsshared move
Sana Biotechnology to Present at May 2023 Investor Conferences
Sana Biotechnology, Inc. announced its participation in two investor conferences in May 2023, where key executives will present business updates. Steve Harr, the President and CEO, will present at the BofA Securities 2023 Healthcare Conference on May 9, while CFO Nate Hardy will present at the JMP Securities Life Sciences Conference on May 15. The presentations will be available via webcast on the company’s website, with replays accessible for 30 days following the events.
Read more →SANA▼ -7.7%on this newsshared move
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Sana Biotechnology, Inc. announced the acceptance of six abstracts for presentation at the American Society of Gene and Cell Therapy’s 26th Annual Meeting. The abstracts highlight important preclinical findings from Sana's fusogen platform, encompassing innovative techniques and promising results for CAR T therapies. Presentations will take place from May 16-20, 2023, in Los Angeles, CA. The company aims to enhance gene delivery methods and the manufacturing process for their therapies.
Read more →SANASana Biotechnology to Host Research & Development Day
Sana Biotechnology, Inc. announced that it will host a Research & Development Day on May 23, 2023, in New York, NY. The event aims to provide a comprehensive overview of the company's R&D portfolio, specifically focusing on programs related to hypoimmune and fusogen platforms. Attendees will receive detailed insights into clinical trials for candidates like SC291 and hypoimmune-modified islet cells for type 1 diabetes. Additionally, a live webcast of the event will be accessible via Sana's Investor Relations page.
Read more →SANASana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
Sana Biotechnology presented notable preclinical data at the 2023 AACR Annual Meeting, highlighting advancements in its allogeneic CAR T platform and its in vivo fusogen platform. The research demonstrated that hypoimmune-modified CD19-directed CAR T cells exhibit lasting functionality in allogeneic models, showing robust tumor control. Additionally, the company reported significant improvements in the manufacturing of fusosomes, enhancing their potency significantly. Upcoming clinical data and IND filings for various CAR T therapies are anticipated by the end of 2023, suggesting a promising future for treating hematological cancers.
Read more →SANA▲ +30.7%on this news· ran to +48% by day 3
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
Sana Biotechnology has published preclinical data in Nature Communications detailing the efficacy of its hypoimmune allogeneic CD19-directed CAR T cells. These engineered cells showed enhanced tumor-killing capabilities and the ability to evade immune detection in humanized mouse models. The findings suggest potential long-term therapeutic benefits for patients with B-cell malignancies, with initial clinical results for SC291 expected later this year and an IND submission for a second therapy, SC262. Overall, the data indicate a significant advancement in CAR T cell technology that may overcome existing limitations.
Read more →SANASana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization Dr. Douglas E. Williams as Head of Research and Development Dr. Gary Meininger as Chief Medical
Sana Biotechnology has announced the appointments of Dr. Douglas E. Williams as President of Research and Development and Dr. Gary Meininger as Chief Medical Officer. Both leaders bring decades of experience in drug development and innovation, enhancing Sana's capabilities. Dr. Williams has previously led R&D efforts at notable biotech firms, while Dr. Meininger has significant clinical development experience. The transition marks a strategic shift for the company as it focuses on delivering gene and cell-based therapies.
Read more →SANASana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Announced SC291 IND clearance with goal to report initial clinical data this year Expect to initiate investigator-sponso
Sana Biotechnology has announced its financial results for the fourth quarter and full year 2022, highlighting significant advancements in its clinical programs. The company received IND clearance for SC291, a therapy aimed at B-cell malignancies, and plans to initiate further trials this year. With a strong cash position of $434 million, Sana aims to submit additional INDs and deliver clinical data across various platforms in the near future. These developments position the company for accelerated growth in the coming years.
Read more →SANASana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
Sana Biotechnology announced the acceptance of four abstracts for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL. Among these is a late-breaking abstract that emphasizes advances in CAR gene delivery. The company is showcasing data related to its hypoimmune and fusogen platforms, reflecting its commitment to engineered cell therapies. This presentation opportunity underscores Sana's ongoing research and potential contributions to cancer treatment advancements.
Read more →SANASana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
Sana Biotechnology, Inc. announced its participation in the Cowen 43rd Annual Health Care Conference, where it will webcast a presentation featuring updates from CEO Steve Harr. The event is scheduled for March 8, 2023, at 9:50 a.m. ET, and will be accessible on Sana's Investor Relations page. This presentation aims to provide insights into the company's business, its focus on engineered cell therapies, and its vision for treating diseases.
Read more →SANASana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
Sana Biotechnology, Inc. will present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference on February 9, 2023. The event will include a webcast of a business overview and updates from CEO Steve Harr. Attendees can access the presentation via the Investor Relations page on Sana's website, with a replay available for 30 days. This participation underlines Sana's commitment to developing engineered cell therapies for patients.
Read more →SANASana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies Goal is to report initial
Sana Biotechnology announced that the FDA has cleared its Investigational New Drug application for SC291, a CD19-targeted allogeneic CAR T therapy, aiming to treat patients with B-cell malignancies. The hypoimmune-modified platform is designed to minimize immunologic rejection of transplanted cells. The company plans to report initial clinical data for SC291 later this year and is also preparing a second IND application for another CAR T therapy targeting CD22. This development underscores Sana's commitment to advancing engineered cell therapies for challenging cancers.
Read more →SANA▼ -5.6%on this news
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
Sana Biotechnology, Inc. announced that it will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. CEO Steve Harr will deliver an overview of the company's business strategy and progress. Attendees can access the presentation via Sana's Investor Relations webpage, where a replay will also be available for 30 days. This participation underscores Sana's role in biotechnology and its commitment to developing engineered cell therapies for patients.
Read more →SANA▲ +7%on this news
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems Allogeneic HIP CAR T cells can be produced with novel gene editing platfo
Read more →SANASana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
Expect to file IND this year for SC291 with potential clinical data in 2023 Expect to file INDs for SG295 and SC263 in 2023; SC451 and BCMA-targeted CAR T in 2024 Will discontinue internal investment for SC187 (cardiomyocytes in heart failure) Prioritization and restructuring
Read more →SANASana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it has been named the top place to work on the BioSpace 2023 Best Places to Work small employer lis
Read more →SANA▼ -13.9%on this news
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts have been accepted for presentation, including two oral presentations, at the 64th Am
Read more →SANASana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates Expect to file IND this year for SC291 with potential clinical data in 2023 Followed by expected INDs for SG295 and SC276 in 2023 and S
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates Expect to file IND this year for SC291 with potential clinical data in 2023 Followed by expected INDs for SG295 and SC276 in 2023 and SC451 in 2024 with potential clinical data in 2024 Q3 2022
Read more →SANASana Biotechnology to Present at September 2022 Investor Conferences
SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentations at two investor conferences in September. The presentations will
Read more →SANA▲ +10.1%on this news· ran to +22% by day 1
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings f
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as w
Read more →SANA▲ +21.5%on this news· ran to +58% by day 3
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression The islet autoimmune data suggest that cells with hypoimmune (HIP) edit
Read more →SANA▼ -10.5%on this newsshared move
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting
SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will present data from its hypoimmune platform at the International Society for Stem Ce
Read more →SANA▲ +5.5%on this news
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4
Read more →SANASana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory Replacement of Fremont, CA Facility Estimated to Save Over $100M in the Ne
Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Replacement of Fremont, CA Facility Estimated to Save Over $100M in the Next Three Years Global Cell Therapy Manufacturing Expert Snehal Patel
Read more →SANA▼ -10.6%on this news
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive
Read more →SANA▲ +9.1%on this newsshared move
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allo
Read more →SANA▲ +8.6%on this news· ran to -28% by day 3
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference at 3:20 p.m. PT o
Read more →SANASana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts covering preclinical data from its hypoimmune and fusogen platforms were accepted for
Read more →SANA▲ +11.1%on this news
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program,
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022 2021 year-end
Read more →SANA▲ +9.9%on this news
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 32nd Annual Oppenheimer Healthcare Conference at 6:20 a.m.
Read more →SANASana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data from its hypoimmune T cell program will be presented at the 2022 American Associa
Read more →SANASana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA
Read more →SANASana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio
Read more →SANASana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m.
Read more →SANASana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional CAR T cells in vivo, demonstrating T cell-specific delivery and therapeutic funct
Read more →SANASana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates Announced license agreement for Beam's CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash
Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates Announced license agreement for Beam's CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million SEATTLE - November 8, 2021 - S
Read more →SANASana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four poster presentations at the 63rd American Society of Hematology
Read more →SANAand clinical and regulatory development plans and timing expectations; the use and utility of the Cas12b nuclease system for Sana's ex vivo engineered cell programs; and Sana's potential milestone , royalty and other pay
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs Agreement combines Beam's gene editing technology with Sana's ex vivo platform SEATTLE - October 19, 2021 - Sana Biotechnology,
Read more →SANASana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
Agreement combines Beam’s gene editing technology with Sana’s ex vivo platform SEATTLE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered
Read more →SANACautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities
Corporate Presentation September 2021 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws. All statemen
Read more →SANASana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Morgan Stanley 19th Annual Global Healthcare Conference at
Read more →SANA▲ +5.7%on this news
Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression
Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression at ISSCR 2021 Entered long-term lease to establish manufac
Read more →SANASana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates
Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies Facility Able to Support Clinical Trial and Early Commercial Launches of Multiple Programs State-of-the-Art Manufacturing Facility to be Located in San Francisco Bay Area SEATTLE, July 14, 2021
Read more →SANASana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression Transplanting allogeneic cells into a primate without immune suppression represents a key step toward widespread treatment
Read more →SANASana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Rese
Read more →SANASana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1
Read more →SANASana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates Presented key proof of concept data for multiple platforms at AACR 2021 Q1 2021 cash position of $981.9 million SEATTLE
Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates Presented key proof of concept data for multiple platforms at AACR 2021 Q1 2021 cash position of $981.9 million SEATTLE - May 5, 2021 - Sana Biotechnology, Inc. (NASDAQ: SANA), a company focus
Read more →SANASana Biotechnology to Present at the BofA Securities 2021 Healthcare Conference
SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the BofA Securities 2021 Healthcare Conference at 8:00 a.m. PT o
Read more →SANASana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes — SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and deliv
Read more →SANASana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication – – Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tumor eradication – SEATTLE, April 09, 2021 (GLOBE NEWSWIRE) -- Sana Biotechn
Read more →SANASana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthene
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds SE
Read more →SANASana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering of 27,025,000 shares of its common stock at a public
Read more →SANASana Announces Upsized Pricing of Initial Public Offering
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a
Read more →Competitive Position
How SANA ranks across every disease it competes inCompetitive Position is a premium feature
See how SANA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial